Abzena Ltd, a CDMO and CRO for complex biologics and bioconjugates, has appointed Taylor Boyd as chief business officer, a new role involving corporate development, and portfolio and partnering strategy. Mr Boyd will play a role in shaping Abzena's strategic growth, particularly by acquiring or licensing new technologies that improve the development of antibodies and other treatments. Mr. Boyd, who previously was an investment banker covering the biopharmaceutical sector, most recently was head of business development at Longboard Pharmaceuticals. He also was vice president of investor relations at Oxford Biomedica Plc. Abzena has research, development and cGMP facilities in San Diego and Bristol, US and Cambridge, UK.
Abzena announced the appointment on 26 February 2025.
Copyright 2025 Evernow Publishing Ltd.